EBOLA FEVER

Cover Page


Cite item

Full Text

Abstract

Problems of etiology, taxonomy and nomenclature of filoviruses, epidemiology, morbidity with a little-known by Russian medics especially dangerous exotic infectious disease - Ebola fever are examined. Significant distinguishing features of 2013 - 2015 epidemic in West Africa were detected - along with its unprecedented length, a decline did not take place as in previous outbreaks, neither causative agent virulence, nor infectivity of the infection during multiple generations from human to human. Literature data analysis allowed to assume that in the process of epidemic focus formation Ebola virus changes its properties and cyclically passes through several successive interconnected phases: an initial reservation phase in unknown ecosystems - animals, either plant, soil or water; intermediate phase of epidemic spread with primary acquisition of high virulence for humans, and then its decline; final stage of hidden circulation of causative agent that is ap-athogenic for humans. This hypothetical chain of natural phases’ transitions of Ebola virus allows to explain and link together phenomenology of this causative agent - rapid fall of virulence and infectivity for humans in foci in dynamics of epidemic outbreaks, quite a high population immunity in nosoareal of the causative agent in Africa, that contradicts the established understanding of its high lethality for humans.

About the authors

V. A. Markin

48th Central Research Institute of the Ministry of Defense of Russian Federation

Author for correspondence.
Email: noemail@neicon.ru
Россия

V. B. Pantyukhov

48th Central Research Institute of the Ministry of Defense of Russian Federation

Email: noemail@neicon.ru
Россия

References

  1. Бэрон Р.К., Маккормик Д.В., Зубейр О.А. Внутрибольничная и внутрисемейная передача лихорадки Эбола в южном районе Судана. Бюлл. ВОЗ. 1983, 61 (6): 83-89.
  2. Маркин В.А. Методология коллекционирования патогенов. Вопр. вирусол. 2010, 5: 4- 9.
  3. Маркин В.А Патогенетический подход для выбора перспективных путей противовирусной терапии. Журн. микробиол. 2014, 3: 114-124.
  4. Покровский В.И., Пак С.Г., Брико Н.И., Данилкин Б.К. Инфекционные болезни и эпидемиология. ГЭОТАР-Медиа, 2008.
  5. Baize S., Leroy Е.М., Georges A.J. et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 2002, 128 (1): 163-168.
  6. BaslerC.F. Portrait of a Killer: Genome of the 2014 EBOVoutbreak strain. Cell. Host. Microbe. 2014, 16 (4): 419-421.
  7. Becquart R, Wauquier N., Mahlakoiv T. et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One. 2010, 5 (2): e9126.
  8. Discussions and decisions of the 2012 - 2014 International Committee on taxonomy of viruses. Filoviridae study group. Jan 2013. Arch. Virol. doi: 10.1007/s00705-013-1846-9.
  9. Ebola update. A ProMed-mail post. URL //www.promedmail.org (дата обращения - 20.12.2015).
  10. Ebola vims haemorrhagic fever. Pattin S.R. (ed.). Antwerpen. 1978.
  11. Eggo R.M., Watson C.H., Camacho A. et al. Duration of Ebola vims RNA persistence in semen of SUR level estimates and projections. Eurosurveillance. 2015, 20 (48): art. 21326.
  12. Fauci A.S. Ebola - underscoring the global disparities in health care resources Anthony. N. Engl. J. Med. 2014, 371: 1084-1086.
  13. Feldman H., Geisbert T.W. Ebola haemorrhagic fever. Lancet. 2011, 377: 849-862.
  14. Filoviridae: Vims Ebola - vims Marburg / Raport sur le fonctionnement technique 1984-85. Inst. Pasteur, Bangui, 1985, p. 17-59.
  15. Hughes M., Slenczka W., Neppert J. Serologic evidence for the occurrence of human infections with Marburg and Ebola vims in the Republic of Liberia. Zbl. Microbiol. Ugd. 1987, 1: 128 - 130.
  16. Johnson E.D., Gonzales J.P., Georges A. Filovims activity among selected ethnic groups inhabiting the tropical forest of equatorial Africa. Trans. Roy. Soc. Trop. Med. Hyg. 1993,87 (5): 536-538.
  17. Johnson K.M. African haemorrhagic fever due to Marburg and Ebola vimses. Viral infection of humans. Epidemiology and Control. Evans A.S. (ed.). N.Y., 1989, p. 85-94.
  18. Johnson K.M. African haemorrhagic fever caused by Marburg and Ebola vimses. Viral infection of humans. Epidemiology and Control. Evans A.S. (ed.). N.Y., 1989, p. 95-104.
  19. Kilgore P.E., Grabenstein J.D., Salim A.M. et al. Treatment of Ebola vims disease. Pharmacotherapy. 2015, 35 (1): 43-53.
  20. Lahm S.A., Kombila M., Swanepoel R. et al. Morbidity and mortality of wild animals in relation to outbreaks of Ebola haemorrhagic fever in Gabon, 1994-2003. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:64-78.
  21. Leroy E.M., Rouquet R, Formenty P. Multiple Ebola vims transmission events and rapid decline of Central African wildlife. Science. 2004. 303: 387-390.
  22. Leroy E.M., Epelboin A., Mondonge V. et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vect. Bom. Zoon. Dis. 2009, 9 (6): 723-728.
  23. Michak J.H., Bressler D.S., Rossi C.A. Short report: Lack of virus replication in arthropods after intrathoracic inoculation of Ebola Reston vims. Am. J. Trap. Med. Hyg. 1996, 55 (1): 89-90.
  24. OlivalKJ., HaymanD.T. Filovirusesinbats: Current knowledge and future directions. Vimses. 2014,6: 1759-1788.
  25. Outbreaks Chronology: Ebola Vims Disease. URL http://www.cdc.gov/vhf/ebola/outbreaks/ history/chronology.html (дата обращения -20.12.2015).
  26. Pourrut X., Souris M., Towner J.S. et al. Large serological survey showing со circulation of Ebola and Marburg vimses in gabonese bat populations and a high seroprevalence of both vimses in Rousettus aegyptiacus. BMC Infect. Dis. 2009, 9: 159-165.
  27. Prescott J., BushmakerN., Fischer R. et al. Postmortem stability of Ebola vims. Emerg. Infect. Dis. 2015, 21 (5): 58-65.
  28. Reiter P., Turell M., Coleman R. et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo: Arthropod studies. J. Infect. Dis. 1999,179: 148-154.
  29. Schumann M., Gantke T., Muhlberger E. Ebola vims VP35 antagonizes PKR activity trough its C-terminal interferon inhibitory domain. J. Virol. 2009, 83: 8993-8997.
  30. Simmons G., Wool-Lewis R. J., Baribaud F. et al. Ebola vims glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002, 76: 2518-2528.
  31. Surean P. Infections a vims Marburg et Ebola / Inst. Pasteur - Cours de Microbiologie Systematique (virologie) 1982-83. Bangui, 1983, p. 85-94.
  32. Vims taxonomy: The classification and nomenclature of vimses. The seventh report of the international committee on taxonomy of vimses. van Regenmortel M.H. V. et al. (ed.). Academic Press, San Diego, 2000.
  33. Vims taxonomy: The classification and nomenclature of vimses. Ninth report of the international committee on taxonomy of vimses. King A.M.Q. et al. (ed.). Elsevier, Amsterdam, 2012.
  34. Wahl-Jensen V, Kurz S. K., Hazelton P. R. et al. Role of Ebola vims secreted glycoproteins and vims-like particles in activation of human macrophages. J. Virol. 2005, 79: 2413-2419.
  35. Weik M., Modrof J., Klenk H. D. et al. Ebola vims VP30-mediated transcription is regulated by RNA secondary stmcture formation. J. Virol. 2002, 76: 8532-8539.
  36. Westwood J.C.N. The hazard from dangerous exotic diseases. McMillan Press, 1980.
  37. WHO Ebola Response Team. Ebola Vims Disease in West Africa - The First 9 Months of the Epidemic and Forward Projections. N. Engl. J. Med. 2014, 371: 1481-1495.
  38. Yuan J., Zhang Y., Li J. et al. Serological evidence of ebolavims infection in bats, China. J. Virol. 2012, 9: 236-245.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Markin V.A., Pantyukhov V.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies